Time to first disease progression, but not β2‐microglobulin, predicts outcome in myeloma patients who receive thalidomide as salvage therapy
暂无分享,去创建一个
M. Boccadoro | F. Gay | S. Bringhen | F. Cavallo | A. Palumbo | B. Bruno | T. Caravita | P. Falco | M. T. Ambrosini | I. Avonto